The role of genotyping in diagnosing cardiac channelopathies: Progress to date

Molecular Diagnosis

Volumn 9, Issue 3, 2005, Pages 105-118

  Vincent, G Michael ^a,b   Zhang, Li ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Physician Office Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ION CHANNEL;

ANDERSEN SYNDROME; BRUGADA SYNDROME; CARDIAC ION CHANNELOPATHY; FAMILY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE TACHYCARDIA; HUMAN; LABORATORY; LONG QT SYNDROME; MASS SCREENING; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MUTATION; PATHOPHYSIOLOGY; PHENOTYPE; PROGRESSIVE CARDIAC CONDUCTION SYSTEM DISEASE; REVIEW; SHORT QT SYNDROME; SUDDEN DEATH; SYNCOPE; SYNDACTYLY; TIMOTHY SYNDROME;

GENOTYPE; HEART DISEASES; HUMANS;

EID: 27744462989     PISSN: 10848592     EISSN: 10848592     Source Type: Journal    
DOI: 10.2165/00066982-200509030-00001     Document Type: Review

References (129)

1. Ackerman MJ. Cardiac channelopathies: it's in the genes. Nat Med 2004; 10: 463-4
2. Charpentier F, Demolombe S, Escande D. Cardiac channelopathies: from men to mice. Ann Med 2004; 36 Suppl. 1: 28-34
3. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. Circ Res 2004; 94: 140-5
4. Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102: 1178-85
5. Brugada P, Geelen P. Some electrocardiographic patterns predicting sudden cardiac death that every doctor should recognize. Acta Cardiol 1997; 52: 473-84
6. Brugada P, Brugada J, Brugada R. Dealing with biological variation in the Brugada syndrome. Eur Heart J 2001; 22: 2231-2
7. Donaldson MR, Yoon G, Fu YH, et al. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med 2004; 36 Suppl. 1: 92-7
8. Vincent GM, Timothy KW, Leppert M, et al. The spectrum of symptoms and QT intervals in the carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327: 846-52
9. Vincent GM. Heterogeneity in the inherited long QT syndrome. J Cardiovasc Electrophysiol 1995; 6: 137-46
10. Dreifus LS, Soffer J. Drug-induced ventricular arrhythmias: prolonged QT interval. Am Fam Physician 1981; 24: 203-4
11. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15: 475-95
12. Mitcheson JS, Chen L, Lin M, et al. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000; 97 (22): 12329-33
13. Woosley RL. Discovering adverse reactions: why does it take so long? Clin Pharmacol Ther 2004; 76: 287-9
14. Ackerman MJ, Khositseth A, Tester DJ, et al. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77: 413-21
15. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510-5
16. Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003; 41: 633-42
17. Naomasa M, Minoru H, Takeshi N, et al. Drug-induced long QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002; 106: 1269-74
18. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrythmias. J Cardiovasc Electrophysiol 2000; 11: 691-6
19. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 2004; 82: 182-8
20. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-9
21. Mohler PJ, Splawski I, Napolitano C, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A 2004; 101: 9137-42
22. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 19-31
23. Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002; 110: 381-8
24. Ackerman MJ, Tester DJ, Driscoll DJ. Molecular autopsy of sudden unexplained death in the young. Am J Forsensic Med Pathol 2001; 22: 105-11
25. Chugh SS, Senashova O, Watts A, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 2004; 43: 1625-9
26. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval, and sudden death. Am Heart J 1957; 54: 59-68
27. Romano C, Genrme G, Pongiglione R. Aritmie cardiache rare dell'eta pediatrica. Clin Pediatr 1963; 45: 656-83
28. Romano C. Congenital cardiac arrhythmia. Lancet 1965; I: 658-9
29. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc 1964; 54: 103-6
30. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992; 20: 1391-6
31. Keating MT, Atkinson D, Dunn C, et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991; 252: 704-6
32. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12: 17-23
33. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmias. Cell 1999; 97: 175-87
34. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803
35. Schott JJ, Charpentier F, Peltier S, et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995; 57: 1114-22
36. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23: 20-1
37. Schulze-Bahr E, Wang Q, Wedekind H, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 1997; 17: 267-8
38. Tyson J, Tranebjaerg L, Bellman S, et al. IsK and KvLQT1: mutation in either of the two subunits of the slow component of the delayed rectifier potassium channel can cause Jervell and Lange-Nielsen syndrome. Hum Mol Genet 1997; 6: 2179-85
39. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-11
40. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293-6
41. GeneTests [online]. Seattle (WA): University of Washington, 2005. Available from URL: http://www.genetests.org/ [Accessed 2005 Oct 18]
42. Splawski I, Timothy KW, Sharpe LM, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004; 119: 1-20
43. van Langen IM, Birnie E, Alders M, et al. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. J Med Genet 2003; 40: 141-5
44. Schulze-Bahr E, Eckardt L, Breithardt G, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat 2003; 21: 651-2
45. Zhang L, Vincent GM, Baralle M, et al. An intronic mutation causes long QT syndrome. J Am Coll Cardiol 2004; 44: 1283-91
46. Ackerman MJ, Tester DJ, Jones GS, et al. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78: 1479-87
47. Sharma D, Glatter KA, Timofeyev V, et al. Characterization of a KCNQ1/ KVLQT1 polymorphism in Asian families with LQT2: implications for genetic testing. J Mol Cell Cardiol 2004; 37: 79-89
48. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297: 1333-6
49. Priori SG, Napolitano C. Genetics of cardiac arrhythmias and sudden cardiac death. Ann N Y Acad Sci 2004; 1015: 96-110
50. Towbin JA. Molecular genetic basis of sudden cardiac death. Pediatr Clin North Am 2004; 51: 1229-55
51. van Langen IM, Hofman N, Tan HL, et al. Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med 2004; 36 Suppl. 1: 116-24
52. Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol 2004; 43: 1137-44
53. Di Paolo M, Luchini D, Bloise R, et al. Postmortem molecular analysis in victims of sudden unexplained death. Am J Forensic Med Pathol 2004; 25: 182-4
54. Quaglini S, Rognoni C, Priori SG, et al. Cost-effectiveness of neonatal ECG as a screening for long QT-syndrome: a decision analysis approach [abstract]. Medinfo 2004; 2004: 1821
55. Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1709-14
56. Schwartz PJ, Priori SG, Dumaine R, et al. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med 2000; 343: 262-7
57. Schwartz PJ. Stillbirths, sudden infant deaths, and long-QT syndrome: puzzle or mosaic, the pieces of the jigsaw are being fitted together. Circulation 2004; 109: 2930-2
58. Towbin JA, Friedman RA. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1760-1
59. Towbin JA, Ackerman MJ. Cardiac sodium channel gene mutations and sudden infant death syndrome. Circulation 2001; 104: 1092-3
60. Ward OC. The electrocardiographic abnormality in familial cardiac arrhythmia. Ir J Med Sci 1966; 6 (491): 553-7
61. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long QT syndrome clinical impact. Circulation 1999; 99: 529-33
62. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-44
63. Vincent GM. Long QT syndrome. Cardiol Clin 2000; 18: 309-25
64. Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome: an update. Circulation 1993; 88: 782-4
65. Lehmann MH, Suzuki F, Fromm BS, et al. T wave 'humps' as a potential electrocardiographic marker of the long QT syndrome. J Am Coll Cardiol 1994; 24: 746-54
66. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-34
67. Zhang L, Timothy KW, Vincent GM, et al. The spectrum of ST-T wave patterns and repolarization parameters in congenital long QT syndrome: ECG findings identify genotype. Circulation 2000; 102: 2849-55
68. Shimizu W, Antzelevitch C. Differential response of beta-adrenergic agonists, antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35: 778-86
69. Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhyth-mic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004; 44: 117-25
70. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002; 105: 794-9
71. Westenskow P, Splawski I, Timothy KW, et al. Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004; 109: 1834-41
72. Yamaguchi M, Shimizu M, Ino H, et al. Compound heterozygosity for mutations (D611Y in KCNQ1, D609G in KCNH2) associated with severe long QT syndrome. Clin Sci (Lond) 2005; 108 (2): 143-50
73. Yamaguchi M, Shimizu M, Ino H, et al. Compound heterozygosity for mutations Asp(611)→Tyr in KCNQ1 and Asp(609)→Gly in KCNH2 associated with severe long QT syndrome. Clin Sci (Lond) 2005; 108: 143-50
74. Moss AJ. Management of patients with the hereditary long QT syndrome. J Cardiovasc Electrophysiol 1998; 9: 668-74
75. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long QT syndrome. Circulation 2000; 101: 616-23
76. Schwartz PJ, Priori SG, Cerrone M, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004; 109: 1826-33
77. Villain E, Denjoy I, Lupoglazoff JM, et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J 2004; 25: 1405-11
78. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 2000; 11: 593-600
79. Breithardt G, Wichter T, Haverkamp W, et al. Implantable cardioverter defibril-lator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, or no structural heart disease. Am Heart J 1994; 127: 1151-8
80. Cieslinski G, Kadel C, Schrader R, et al. Implantable defibrillator in the long QT syndrome [in German]. Dtsch Med Wochenschr 1995; 120: 283-8
81. Groh WJ, Silka MJ, Oliver RP, et al. Use of implantable cardioverter-defibrillators in the congenital long QT syndrome. Am J Cardiol 1996; 78: 703-6
82. Zareba W, Moss AJ, Daubert JP, et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003; 14: 337-41
83. Etheridge SP, Compton SJ, Tristani-Firouzi M, et al. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42: 1777-82
84. Schwartz PJ, Priori SG, Locati EH. QTc responses to mexiletine and to heart rate changes differentiate LQT1 from LQT3 but not from LQT2 patients. Circulation 1996; 94: I204
85. Windle JR, Geletka RC, Moss AJ, et al. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A: DeltaKPQ mutation. Ann Noninvasive Electrocardiol 2001; 6: 153-8
86. Zhang L, Benson DW, Tristani-Firouzi M, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations. Circulation 2005; May 31; 111 (21): 2720-6
87. Andersen E, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extra-systoles, and multiple developmental anomalies: a new syndrome? Acta Paediatr Scand 1971; 60: 559-64
88. Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994; 35: 326-30
89. Zhang L, Benson DW, Timothy KW, et al. ECG T-U wave patterns predict genotype of Andersen syndrome patients with KCNJ2 mutations [abstract]. Circulation 2003; 108: 2303
90. Marks ML, Trippel DL, Keating MT. Long QT syndrome associated with syndactyly identified in females. Am J Cardiol 1995; 76: 744-5
91. Marks ML, Whisler SL, Clericuzio C, et al. A new form of long QT syndrome associated with syndactyly. J Am Coll Cardiol 1995; 25: 59-64
92. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation 2003; 108: 965-70
93. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30-5
94. Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109: 2394-7
95. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96: 800-7
96. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 2004; 43: 1494-9
97. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336: 905-11
98. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299: 251-4
99. Yang Y, Xia M, Jin Q, et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet 2004; 75: 899-905
100. Brugada P, Brugada R, Brugada J. Sudden death in high-risk family members: Brugada syndrome. Am J Cardiol 2000; 86: K40-3
101. Brugada P, Brugada R, Brugada J. The Brugada syndrome. Curr Cardiol Rep 2000; 2: 507-14
102. Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002; 106: 2514-9
103. Martini B, Nava A. 1988-2003. Fifteen years after the first Italian description by Nava-Martini-Thiene and colleagues of a new syndrome (different from the Brugada syndrome?) in the Giornale Italiano di Cardiologia: do we really know everything on this entity? Ital Heart J 2004; 5: 53-60
104. Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96: 2595-600
105. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002; 11: 337-45
106. Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation 2002; 105: 707-13
107. Antzelevitch C, Brugada P, Brugada J, et al. Brugada syndrome: a decade of progress. Circ Res 2002; 91: 1114-8
108. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the Second Consensus Conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; Feb 8; 111 (5): 659-70
109. Bezzina C, Veldkamp MW, van den Berg MP, et al. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999; 85: 1206-13
110. Rivolta I, Abriel H, Tateyama M, et al. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J Biol Chem 2001; 276: 30623-30
111. Veldkamp MW, Viswanathan PC, Bezzina C, et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. Circ Res 2000; 86: E91-7
112. Junttila MJ, Raatikainen MJ, Karjalainen J, et al. Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population. Eur Heart J 2004; 25: 874-8
113. Ahn J, Hurst JW. Worrisome thoughts about the diagnosis and treatment of patients with Brugada waves and the Brugada syndrome. Circulation 2004; 109: 1463-7
114. Yamakawa Y, Ishikawa T, Uchino K, et al. Prevalence of right bundle-branch block and right precordial ST-segment elevation (Brugada-type electrocardio-gram) in Japanese children. Circ J 2004; 68: 275-9
115. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002; 40: 350-6
116. Beldner S, Lin D, Marchlinski FE. Flecainide and propafenone induced ST-segment elevation in patients with atrial fibrillation: clue to specificity of Brugada-type electrocardiographic changes. Am J Cardiol 2004; 94: 1184-5
117. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108: 3092-6
118. Hong K, Brugada J, Oliva A, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004; 110: 3023-7
119. Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 2000; 102: 2509-15
120. Brugada P, Brugada R, Mont L, et al. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol 2003; 14: 455-7
121. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6
122. Tan HL, Bink-Boelkens MT, Bezzina CR, et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001; 409: 1043-7
123. Wang DW, Viswanathan PC, Balser JR, et al. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduc-tion block. Circulation 2002; 105: 341-6
124. Coumel P. Polymorphous ventricular tachyarrhythmias in the absence of structural heart disease. Pacing Clin Electrophysiol 1997; 20: 2065-7
125. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 2000; 34: 2035-42
126. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventircular tachycardia. Circulation 2001; 103: 196-200
127. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378-84
128. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal recessive catecholamine-or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001; 103: 2822-7
129. Laitinen PJ, Swan H, Piippo K, et al. Genes, exercise and sudden death: molecular basis of familial catecholaminergic polymorphic ventricular tachycardia. Ann Med 2004; 36 Suppl. 1: 81-6